SEC Comment Letter for Emergent BioSolutions Inc. (EBS) (CIK 0001367644) (EBS) — Dec 9, 2021

Emergent BioSolutions Inc. (EBS) (CIK 0001367644)
Date: Dec. 9, 2021 · CIK: 0001367644 · Accession: 0000000000-21-014791

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-33137

Date

December 9, 2021

Author

Richard Lindahl

Form

UPLOAD

Company

Emergent BioSolutions Inc. (EBS) (CIK 0001367644)

Letter

United States securities and exchange commission logo December 9, 2021 Richard Lindahl Chief Financial Officer Emergent BioSolutions Inc. 400 Professional Drive Suite 400 Gaithersburg, Maryland Re:Emergent BioSolutions Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 File No. 001-33137 Dear Mr. Lindahl: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
December 9, 2021
Richard Lindahl
Chief Financial Officer
Emergent BioSolutions Inc.
400 Professional Drive Suite 400
Gaithersburg, Maryland
Re:Emergent BioSolutions Inc.
Form 10-K for the Fiscal Year Ended December 31, 2020
File No. 001-33137
Dear Mr. Lindahl:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io